## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. Ser. No. : 10/040,128

Inventor : LIAO et al.

Filing Date : January 2, 2002

Title : ANTIBODY ANTAGONISTS OF

VE-CADHERIN WITHOUT EFFECTS ON

VASCULAR PERMEABILITY

Examiner : Rawlings, S.L.

Group Art Unit : 1643

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450 July 30, 2007

Applicants submit herewith form PTO-1449, which lists an additional reference which has come to the attention of the undersigned.

This submission does not represent that a search has been made or that no better art exists. While the term "references" is used in citing the documents called to the Examiner's attention herein, Applicants do not make any admission that each or all of them are "prior art" references within the meaning of the statutory and case law.

Applicants reserves the right to contend, where appropriate, that a patent asserted against any claim of the present application is not prior art under the facts and the law.

Applicants also reserve the right to present appropriate arguments and/or evidence to establish patentability over the references, should one or more of the references be applied against the claims of the present application.

Applicants request that the Examiner independently determine those items which the Examiner would consider the most pertinent of all the references cited herein.

This Supplemental Information Disclosure Statement is filed before the mailing of any of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application. Form PTO-2038 is enclosed for \$180.00. Any deficiency or should be charged or credited to Deposit Account No. 02-2275. A duplicate of this sheet is enclosed. Accordingly, this document complies with the requirements of 37 C.F.R. Section 1.97(c). It is respectfully requested that the reference cited in the accompanying form PTO-1449 be considered and made of record.

It is respectfully requested that the reference cited in the accompanying PTO-1449 Form be considered and made of record.

Respectfully submitted,

Michael N. Mercanti

LUCAS & MERCA

Reg. No. 33,966

LUCAS & MERCANTI, LLP 475 Park Avenue South New York, New York 10016

Phone: 212-661-8000 Fax: 212-661-8002

<u>CERTIFICATE OF ELECTRONIC TRANSMISSION</u>
I hereby certify that this document is being electronically transmitted to the Commissioner for Patents via

EFS-Web on July 26, 2007.

LUCAS & MERCANTIAL

Michael N. Mercant

Approved for use through 09/30/2007. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Substitute for form 1449/PTO					
Substitute for form (445)	FIO		Application Number	10/040,128	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)			Filing Date	January 2, 2002	
			First Named Inventor	LIAO	
			Art Unit	1643	
			Examiner Name	Rawlings, S.L.	
Sheet 1	of	1	Attorney Docket Number		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		PIGGOT et al. (1991) STRUCTURAL AND FUNCTIONAL STUDIES OF THE ENDOTHELIAL ACTIVATION ANTIGEN ENDOTHELIAL LEUCOCYTE ADHESION MOLECULE-1, J. Immun. 147(1): 130-135.					

		······································
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.